Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Report Third Quarter Financial Results on October 24, 2024 Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, Oct. 24, 2024 to...

Key Takeaway: Alkermes plc will host a conference call and webcast on October 24, 2024, to discuss its third quarter financial results. The event will begin at 8:00 a.m. ET and will be accessible via phone and online. A replay will be available shortly after the event concludes. Alkermes is focused on developing treatments for various neurological disorders.
Price reaction · baseline $28.09 (2024-10-16 close) · hit after-hours · clean, no other ALKS news in the window
day 0 close · peak
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes is set to report its financial results, indicating ongoing business activity.
  • The company continues to develop innovative medicines in neuroscience.
  • The webcast allows for broader investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Thursday, Oct. 24, 2024 to discuss the company's third quarter financial results.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.
About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia . Headquartered in Ireland , Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio . For more information, please visit Alkermes ' website at www.alkermes.com .

Frequently Asked Questions

When will Alkermes report its Q3 financial results?

Alkermes will report its Q3 financial results on October 24, 2024.

How can I access the Alkermes conference call?

The conference call can be accessed by dialing +1 877 407 2988 for U.S. callers.

What time does the Alkermes webcast start?

The Alkermes webcast starts at 8:00 a.m. ET on October 24, 2024.

Where can I find the webcast replay?

The webcast replay will be available on Alkermes' website after the event.

Last updated: Oct 17, 2024